ORGO Organogenesis Holdings (A)

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March

CANTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the following upcoming investor conferences:

The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

  • Management will participate in a virtual fireside chat on Thursday, February 18 at 1:00 p.m. Eastern Time.

The SVBLeerink 10th Annual Global Healthcare Conference

  • Management will participate in a virtual fireside chat on Wednesday, February 24 at 8:40 a.m. Eastern Time.

The Oppenheimer 31st Annual Healthcare Conference

  • Management will present on Wednesday, March 17 at 10:40am Eastern Time.

Live audio webcasts of the conference presentations will be accessible by visiting the “Upcoming Events” section on the “Investor Relations” page of Organogenesis’s website Archives of the webcasts will be available for replay following the conference for approximately 30 days.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit .

Investor Inquiries:

Westwicke Partners

Mike Piccinino, CFA

Press and Media Inquiries:

Organogenesis

Lori Freedman



EN
09/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Organogenesis Holdings (A)

 PRESS RELEASE

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 202...

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, November 6th. Management will host a conference call at 5:00 p.m. East...

 PRESS RELEASE

Organogenesis Provides Update on Second Phase 3 ReNu® Study

Organogenesis Provides Update on Second Phase 3 ReNu® Study Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpointStatistically significant maintenance of function (p

 PRESS RELEASE

Organogenesis Holdings Inc. to Participate in Upcoming Investor Confer...

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences: The Cantor Fitzgerald Global Healthcare Conference at the New York Marriott Marquis in New York, NY Management will partic...

 PRESS RELEASE

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Resu...

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared...

 PRESS RELEASE

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 20...

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Easter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch